NearWave develops advanced medical imaging technology, focusing on a handheld device that utilizes frequency domain near-infrared spectroscopy (fdNIRS) for breast cancer diagnostics. Their NearWave Scanner is designed to assess vital biomarkers, including tissue oxygen saturation and hemoglobin concentrations, non-invasively and without ionizing radiation. This technology aims to assist physicians in selecting optimal therapies for breast cancer patients, potentially reducing unsuccessful treatments and associated side effects.
The company's innovative approach to point-of-care diagnostics represents a significant advancement in medical imaging. NearWave's scanner is notable for its compact size, speed, and ease of use, positioning it as a breakthrough in fdNIRS technology. While currently used for research purposes, the NearWave Scanner shows promise in enhancing breast cancer treatment decisions and improving patient outcomes.
